Pricing Log in Create free account
Saturday 31 October 2026 Export AZN’s income statement to Excel — free account

AstraZeneca PLC

AZN Healthcare Drug Manufacturers General

AstraZeneca PLC’s revenue for fiscal 2025 (year ended December 2025) was $58.7 billion, up 8.63% from fiscal 2024. In the quarter to June 2026, revenue grew 6.41%, EPS grew 1.90%, free cash flow fell 107.5% and total debt fell 5.50%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for five; insiders bought in the last twelve months.

186.38 11.98 +6.87%
Market cap
$270.5B
P/E
27.6×
Fwd P/E
22.4×
Dividend yield
1.72%
F-score
9/9
Altman Z
3.52
Beneish M
−2.51
Dividend safety
54/100
Overview Business Profile Financial Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions trades per month

Total buys 0.00
Total sells 2.21
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — 1 — —
Sell — — — — — — 1 — — — — —
Insider Ownership 3.29%

Capital & Financial Ratios $m

Market Cap 270,480.00
Revenue 61,366.00
Net Income 12,586.00
Free Cash Flow 6,265.00
Net Debt 24,447.00
Current Ratio 0.89 (below 1: weak)
Debt/Equity 0.59
P/E ratio 27.65
Fwd P/E 22.40
P/S ratio 4.71
P/B ratio 5.74
Past 5Y EPS Growth 21.82% (at or above 15%: strong)
This Y EPS Growth 11.93%
Next Y EPS Growth 11.51%
Next Y revenue growth 7.75%
Next 5Y EPS Growth 11.59%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 5.1×, against a ten-year median of 5.1×; over the ten years it ranged from 3.3× in 2016 to 6.4× in 2021.
P/E against its own 10 years 21.95%
10-year low 10-year high
P/S against its own 10 years 61.07%
10-year low 10-year high
P/B against its own 10 years 50.17%
10-year low 10-year high
EV/Sales against its own 10 years 52.59%
10-year low 10-year high
EV/FCF against its own 10 years 89.24%
10-year low 10-year high

Dividends

Payout Ratio 0.48
Annual Dividend Rate 3.21
Annual Dividend Yield 1.72%
total individual payouts
2028 Powerpack
2027 Powerpack
2026 3.21
2.15
1.06
2025 3.13
2.10
1.03
2024 2.97
1.97
1.00
2023 2.90
1.97
0.93
2022 2.90
1.97
0.93
2021 2.80
1.90
0.90
2020 2.80
1.90
0.90
2019 2.80
1.90
0.90
2018 2.80
1.90
0.90
2017 2.80
1.90
0.90
2016 2.80
1.90
0.90
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 6,078 5,708 5,831 5,044
Receivables 13,552 14,831 16,335 15,989
Inventory 5,424 5,288 6,557 6,932
Other — — — —
25,054 25,827 28,723 27,965
2023 2024 2025 Q'26
Payables 22,374 22,465 25,280 22,893
ST’ Debt 5,129 2,337 3,104 5,808
Other 1,184 1,319 767 958
30,542 27,866 30,617 31,553

Compound Annual Growth %

10y 5y 3y
Sales 9.05% 17.15% 9.82%
Cash Flow 15.93% 24.88% 14.11%
Earnings 13.73% 26.19% 45.96%
Book Value 10.16% 25.52% 9.55%

Earnings Trends EPS, adjusted, against the consensus

Jun 2026 Estimate 2.50 Actual 2.63

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Sep 2025 2.28 2.38 Beat by 0.10
Dec 2025 2.18 2.12 Miss by 0.06
Mar 2026 2.57 2.58 Beat by 0.01
Jun 2026 2.50 2.63 Beat by 0.13
Sep 2026 2.60 — Reports 30 October 2026

EPS $

Mar Jun Sep Dec Year
’26 1.97 1.61 — — —
’25 1.86 1.58 1.62 1.48 6.55
’24 1.40 1.24 0.92 0.96 4.50
’23 1.16 1.18 0.88 0.62 3.82
’22 0.26 0.24 1.06 0.58 2.12
’21 1.18 0.42 (1.10) (0.22) 0.08
’20 0.60 0.58 0.50 0.78 2.44
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 15,288 15,384 — — —
’25 13,588 14,457 15,191 15,503 58,739
’24 12,679 12,938 13,565 14,891 54,073
’23 10,879 11,416 11,492 12,024 45,811
’22 11,390 10,771 10,982 11,208 44,351
’21 7,320 8,220 9,866 12,011 37,417
’20 6,354 6,275 6,578 7,410 26,617
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 3,359 2,865 — — —
’25 3,713 3,386 5,134 2,342 14,575
’24 2,486 3,085 3,383 2,907 11,861
’23 3,133 1,718 3,114 2,380 10,345
’22 3,232 1,248 2,930 2,398 9,808
’21 1,934 892 1,719 1,418 5,963
’20 139 1,040 1,822 1,798 4,799
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 1,874 (116) — — —
’25 2,754 1,558 3,409 1,098 8,819
’24 1,009 2,417 2,057 1,970 7,453
’23 2,052 1,260 2,240 1,438 6,990
’22 3,254 762 1,836 2,114 7,966
’21 1,887 694 1,076 706 4,363
’20 128 239 1,307 1,576 3,250
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.6
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Price, $
Price, $ Low 49.89 51.95 62.82 69.40 72.30 93.13 104.50 120.60 118.16 122.26 +10.5% ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
High 70.08 71.20 83.56 102.50 126.70 130.40 143.90 153.10 175.00 188.50 +11.6% ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
People
People Employees 59,700 61,100 64,400 70,600 76,100 83,100 83,500 89,900 94,300 96,100 +5.4% ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
Revenue/emp, $m 0.39 0.37 0.34 0.35 0.35 0.45 0.53 0.51 0.57 0.61 +5.3% ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
Income, $m
Income, $m Revenue 23,002 22,465 22,090 24,384 26,617 37,417 44,351 45,811 54,073 58,739 +11.0% 63,292 67,385 71,509 +6.8%
Gross margin, % 82.06 80.78 77.66 79.82 80.09 66.76 72.06 81.95 81.12 81.90 (0.2) pt
EBT 3,552 2,227 1,993 1,548 3,916 (265) 2,501 6,899 8,691 12,402 +14.9%
EBT margin, % 15.44 9.91 9.02 6.35 14.71 (0.71) 5.64 15.06 16.07 21.11 +5.7 pt
Net income 3,552 2,227 1,993 1,548 3,916 (265) 2,501 6,899 8,691 12,402 +14.9%
Depreciation 2,357 3,036 3,753 3,762 3,149 6,530 5,480 5,387 6,688 5,733 +10.4%
Per share, $
Per share, $ Revenue 18.18 17.74 17.43 18.74 20.29 26.39 28.65 29.57 34.89 37.90 +8.5%
Earnings 2.76 2.38 1.70 1.02 2.44 0.08 2.12 3.84 4.54 6.60 +10.2%
Cash flow 3.28 2.83 2.07 2.28 3.66 4.21 6.34 6.68 7.65 9.40 +12.4%
Capex (0.64) (0.13) 0.77 (0.27) (1.18) (1.13) (1.19) (2.17) (2.84) (3.71) +21.7%
Free cash flow 2.64 2.70 2.84 2.02 2.48 3.08 5.15 4.51 4.81 5.69 +8.9%
Book value 13.18 13.15 11.08 11.22 11.92 27.71 23.94 25.28 26.37 31.43 +10.1%
Shares, m 1,265 1,266 1,267 1,301 1,312 1,418 1,548 1,549 1,550 1,550 +2.3%
Valuation, ×
Valuation, × P/E 19.94 28.82 44.68 95.28 41.06 386.17 63.76 34.41 28.59 26.58 76.9
P/S 3.05 3.87 4.36 5.39 4.98 4.39 4.76 4.49 3.73 4.63 4.4
P/B 4.21 5.22 6.85 9.00 8.47 4.18 5.70 5.25 4.93 5.58 5.9
EV/Sales 3.52 4.45 4.95 5.85 5.41 5.01 5.25 4.96 4.16 5.00 4.9
EV/FCF 24.25 29.28 30.42 54.42 44.33 43.00 29.25 32.49 30.16 33.32 35.1
Cash, $m
Cash, $m Operating cash flow 4,145 3,578 2,618 2,969 4,799 5,963 9,808 10,345 11,861 14,575 +15.0%
Capex (805) (161) 979 (347) (1,549) (1,600) (1,842) (3,355) (4,408) (5,756) +24.4%
Free cash flow 3,340 3,417 3,597 2,622 3,250 4,363 7,966 6,990 7,453 8,819 +11.4%
Balance, $m
Balance, $m Working capital (1,994) (3,233) (701) (2,554) (763) 3,650 (3,700) (5,488) (2,039) (1,894) (0.6%)
Total debt 16,808 17,807 19,113 17,552 19,699 29,794 28,279 27,494 28,843 27,819 +5.8%
Net debt 10,879 13,225 13,175 11,298 11,565 23,313 21,787 21,416 23,135 21,988 +8.1%
Shareholders’ equity 16,669 16,642 14,044 14,596 15,638 39,287 37,058 39,166 40,871 48,719 +12.7%
Returns, %
Returns, % ROA 5.71 4.77 3.48 2.19 4.99 0.13 3.26 6.03 6.86 9.38 +3.7 pt
ROIC 11.12 7.69 7.78 7.06 11.86 1.05 3.99 8.45 9.77 12.15 +1.0 pt
ROE 19.89 18.02 14.05 9.32 21.14 0.41 8.61 15.63 17.58 22.83 +2.9 pt
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026

AstraZeneca PLC vs peers in Drug Manufacturers General (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
ABBV AbbVie Inc. $513.9B 83.3× 36.5× +10.16% (above 0%: growing) +290.38% (above 0%: growing) −36.24% (below 0%: shrinking) 74.74% 37.86% Compare
MRK Merck & Co., Inc. $361.0B 120× 106× +5.07% (above 0%: growing) n/m +77.03% (above 0%: growing) 73.54% (2.61%) Compare
NVS Novartis AG $294.9B 24.1× 21.8× +0.78% (above 0%: growing) −17.39% (below 0%: shrinking) −15.53% (below 0%: shrinking) 75.19% 31.77% Compare
AZN AstraZeneca PLC $270.5B 27.6× 22.4× +6.41% (above 0%: growing) +1.90% (above 0%: growing) −107.45% (below 0%: shrinking) 83.60% 20.57%
AMGN Amgen Inc. $249.1B 28.7× 27.9× +9.53% (above 0%: growing) +65.41% (above 0%: growing) +82.57% (above 0%: growing) 72.04% 34.95% Compare
GILD Gilead Sciences, Inc. $205.4B — (loss-making) — (loss-making) +10.18% (above 0%: growing) n/m +376.81% (above 0%: growing) 79.76% (133.21%) Compare
PFE Pfizer Inc. $170.7B 40.1× 18.6× +2.60% (above 0%: growing) n/m +125.17% (above 0%: growing) 72.78% 20.38% Compare
NVO Novo Nordisk A/S $131.0B 9.8× — +4.47% (above 0%: growing) −18.68% (below 0%: shrinking) +71.57% (above 0%: growing) 78.21% 34.48% Compare
BMY Bristol Myers Squibb Company $125.4B 13.8× 11.6× +5.74% (above 0%: growing) +153.13% (above 0%: growing) −13.16% (below 0%: shrinking) 71.28% 31.50% Compare
Median of peers $227.2B 28.7× 24.9× +5.41% +65.41% +74.30% 74.14% 31.64%

All 21 Drug Manufacturers General stocks →

Analyst rating changes each firm’s latest, last six months

Firm Date Action Rating Target
Nordea Oct 20, 2026 Upgrade Sell → Buy —

AstraZeneca PLC (AZN) Latest News

30 Oct

Impact 3 ·
Impact 3 · transcript
Impact 3 ·
Impact 3 ·
Impact 3 ·
Impact 3 ·
Impact 3 ·
Impact 3 ·
Impact 3 ·
Impact 3 ·
Impact 3 ·
Impact 3 ·

29 Oct

Impact 3 ·

28 Oct

Impact 4 ·
Impact 3 ·

27 Oct

Impact 4 ·
Impact 4 ·
Impact 3 ·
Impact 3 ·
Impact 3 ·

26 Oct

Impact 4 ·
Impact 4 ·
Impact 4 ·
Impact 4 ·
Impact 4 ·
Impact 4 ·
Impact 4 ·
Impact 3 ·

25 Oct

Impact 4 ·
Impact 4 ·
stockrow.com/AZN · Data as of Oct 26, 2026 · For information only; not investment advice. · © 2026 stockrow.com